Stifel maintains BioMarin Pharmaceutical at Hold, lowers price target to $66 from $70

What happened

Stifel kept its Hold rating on BioMarin Pharmaceutical and cut its price target to $66 from $70, a 5.7% decrease. The new target implies 14.9% upside from the November 2 close of $57.44.

Confirmed

Global impact / market context

A lower price target signals the analyst sees less upside, though Hold means no strong buy or sell call. Because the target still sits above the current share price, the cut adjusts expectations rather than signaling a collapse in the business outlook.

Analyst inference

Several other firms recently kept Overweight or Buy ratings with targets from $86 to $122, far above Stifel's $66. That gap shows Stifel is more cautious than peers, so its target cut may carry less weight with investors already anchored to higher targets.

Analyst inference

What to watch

1. Watch whether other analysts also lower their targets for BioMarin, since five recent notes ranged from $86 to $122, well above Stifel's new $66 target. Confirmed
2. Watch for any company update on sales, costs, or drug pipeline progress that could justify Stifel's more cautious view or push peers to revise their ratings. Proposed
3. Watch how the share price trades relative to the $66 target, because a move toward it would suggest investors are adopting Stifel's more conservative expectations. Analyst inference

Evidence

• Original source link unavailable